NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

10-22 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	€0.8390	+1.08%	11,865
24/07/26	€0.8300	0.00%	745
23/07/26	€0.8300	0.00%	6,031
22/07/26	€0.8300	-1.78%	3,219
21/07/26	€0.8450	+1.68%	17,201

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 23:55:00 27/07/2026 HKT			5-day change	1st Jan Change
0.8390 ^EUR	+1.08%		+0.96%	-28.78%

07-08	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
07-01	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI

Market Cap	10.63M 12.09M 9.9M 9.09M 17.07M 1.16B 17.29M 118M 45.95M 573M 45.4M 44.42M 1.98B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	9.01M 10.25M 8.39M 7.7M 14.47M 983M 14.66M 99.72M 38.95M 485M 38.49M 37.66M 1.68B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

07-08	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
07-01	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
06-30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
06-02	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
06-02	NFL Biosciences validates breakthrough in personalized medicine
05-26	Glimmers of hope for Middle East peace grow brighter
05-26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
05-26	NFL Biosciences files new patent application
05-25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
05-12	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
05-04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
04-16	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance	CI

21/10/25	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
02/10/24	NFL Biosciences: Invest Securities reduces its target
15/07/24	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Course Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

07-07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
06-30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
05-25	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU
05-11	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101	BU

07-08	NFL Biosciences : Bilan semestriel du contrat de liquidité
07-07	Reconnaissance scientifique internationale pour NFL Biosciences : 3 présentations retenues au congrès SRNT-Europe 2026, dont une communication orale sur NFL-102
06-30	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme
06-30	NFL Biosciences annonce la fabrication avec succès d’un lot clinique GMP de NFL-102 et valide sa chaîne industrielle de production
06-17	NFL Biosciences : compte rendu de l’assemblée générale mixte du 17 juin 2026

1 day	+1.08%
1 week	+0.96%
Current month	-3.56%
1 month	-0.12%
3 months	-19.33%
6 months	-47.56%
Current year	-28.78%

1 week	0.82	0.85
1 month	0.82	0.92
Current year	0.8	1.85
1 year	0.8	1.85
3 years	0.8	3.31
5 years	0.55	5
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	17/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	27/02/2023
Bruno Lafont CHM	Chairman	-	17/10/2024
Francis Ahner BRD	Director/Board Member	-	19/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	+1.08%	+0.96%	-34.25%	-63.20%	12.09M
ARGENX SE	-1.82%	+4.80%	+56.71%	+68.36%	56.19B
WUXI APPTEC CO., LTD.	-0.27%	+0.35%	+40.26%	+79.88%	54.83B
INSMED INCORPORATED	-2.05%	-2.14%	+0.75%	+413.38%	22.7B
BIONTECH SE	+1.97%	-1.16%	-21.00%	-13.25%	23.04B
WUXI BIOLOGICS (CAYMAN) INC.	-0.52%	-0.77%	+20.38%	-11.04%	20.23B
GENMAB A/S	+1.57%	+3.30%	+28.01%	-29.07%	17.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.53%	-2.15%	+31.02%	+540.44%	15.65B
PHARMAESSENTIA CORPORATION	+5.29%	+1.70%	+185.09%	+333.94%	15.24B
EXELIXIS, INC.	+0.79%	+0.50%	+22.39%	+184.74%	14.03B
Average	+0.37%	+0.88%	+32.93%	+150.42%	23.97B
Weighted average by Cap.	-0.19%	+1.07%	+39.45%	+136.38%

	2024	2025
Net sales	46 52.33 42.82 39.32 73.84 5.02K 74.82 508.98 198.79 2.48K 196.43 192.19 8.56K	188 213.86 175 160.72 301.79 20.51K 305.77 2.08K 812.44 10.13K 802.79 785.49 35K
Net income	-2.08M -2.37M -1.94M -1.78M -3.34M -227M -3.38M -23.02M -8.99M -112M -8.89M -8.69M -387M	-3.32M -3.77M -3.09M -2.84M -5.33M -362M -5.4M -36.71M -14.34M -179M -14.17M -13.86M -618M
Net Debt	-2.07M -2.36M -1.93M -1.77M -3.33M -226M -3.37M -22.93M -8.96M -112M -8.85M -8.66M -386M	-1.62M -1.84M -1.51M -1.38M -2.6M -177M -2.63M -17.92M -7M -87.23M -6.92M -6.77M -302M